Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

CERo Therapeutics (CERO) announces the execution of an agreement with contract research organization CellCarta to manage translational assays ...

Biodexa Pharmaceuticals (BDRX) announced the appointment of Precision for Medicine as the clinical research organization, CRO, to conduct the ...

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics, has released its ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

New milestone achieved in Astellas T-cell engager collaboration: In February 2025, Astellas advanced the second program to ...

Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored “window of opportunity” trial into newly diagnosed ...

Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...